
Unithroid is distributed in the United States by Amneal Specialty, a division of Amneal Pharmaceuticals (Nasdaq: AMRX), under a 10-year license and supply agreement with Jerome Stevens Pharmaceuticals, the New York family-owned manufacturer that developed the product and still makes it in Bohemia, New York. Unithroid was the first levothyroxine product to receive FDA approval, in 2000.
Parent Company
Founded
2000
Status
Publicly Traded
Headquarters
| Brand | Parent Company | Ownership Type |
|---|---|---|
| Unithroid | Amneal Pharmaceuticals, Inc. | Licensed |
Jerome Stevens Pharmaceuticals built its business in Bohemia, on Long Island, starting in 1979 as a maker of vitamins and over-the-counter preparations before moving into prescription tablets and capsules. For more than 25 years it manufactured levothyroxine products, largely as an unbranded supplier to other companies' labels.
The FDA's August 1997 decision changed everything. The agency declared all oral levothyroxine sodium products new drugs, meaning every manufacturer needed an approved New Drug Application to stay on the market. Jerome Stevens filed NDA 21-210 on October 19, 1999, covering 11 tablet strengths of Unithroid.
In August 2000, Unithroid became the first levothyroxine product ever to receive FDA approval, ahead of every competitor including Synthroid. The product gained a twelfth strength later, and the FDA designated Unithroid the reference product for the category. Jerome Stevens has said the approval made it the standard against which other levothyroxine tablets were measured.
Distribution initially ran through partners. Watson Pharmaceuticals handled sales early on, followed by Lannett. When the Lannett arrangement expired in March 2019, Jerome Stevens chose Amneal as its next commercial partner, signing the 10-year license and supply agreement announced in August 2018. Amneal described levothyroxine at signing as one of the most compelling generic markets in the country, with more than 120 million annual US prescriptions.
Under Amneal Specialty, Unithroid has been repositioned as a branded specialty product rather than a generic. It was named in Amneal's 2026 earnings commentary as a contributor to Specialty segment growth alongside CREXONT and BREKIYA, evidence that the distribution partnership has turned a quiet legacy approval into an actively managed brand.
Is Amneal Pharmaceuticals publicly traded?
Yes. Amneal Pharmaceuticals, Inc. trades on the Nasdaq under the ticker AMRX. The company went public in May 2018 through its merger with Impax Laboratories.
Who founded Amneal?
Brothers Chirag Patel and Chintu Patel founded Amneal in 2002 in New Jersey. Both men, who are pharmacists by training, continue to serve as co-chief executives of the company.
What does Amneal make?
Amneal manufactures more than 250 pharmaceutical products across generics, injectables, transdermal patches, biosimilars, and branded specialty medicines. Its branded products include CREXONT, BREKIYA, RYTARY, and UNITHROID.
What is Amneal's revenue?
Amneal generated approximately $3.0 billion in net revenue in fiscal 2025 and guided to $3.15 to $3.25 billion for fiscal 2026. Third quarter 2026 revenue was $863 million, up 10 percent year over year.
Does Amneal own UNITHROID?
Amneal distributes UNITHROID through its Amneal Specialty division under a 10-year license and supply agreement signed in 2018 with Jerome Stevens Pharmaceuticals, which continues to manufacture the product in Bohemia, New York.
Where are Amneal's factories?
Amneal operates manufacturing and development sites in New Jersey and New York in the United States, plus facilities in India and Ireland. Its workforce of approximately 7,700 spans 11 countries.
These competing brands operate in the same categories and provide similar products or services. Compare key attributes to understand market positioning and competitive landscape.
| Brand | Parent Company | Country | Founded | Market Position | Primary Market | Gender Target |
|---|---|---|---|---|---|---|
| Pfizer | USA | 2001 | Mass market | United states | All Genders | |
| Abbvie | USA | 1955 | Mass market | United states | All Genders | |
| Abbvie | USA | 1900 | Mass market | United states | All Genders | |
| Ibsa | Switzerland | 2006 | Premium | United states | All Genders | |
| Ibsa | Switzerland | 2016 | Mass market | United states | All Genders |
Healthcare PharmaceuticalsOwned by Pfizer Inc.
Pfizer's levothyroxine brand for hypothyroidism, FDA approved in 2001 and inherited through the 2011 King Pharmaceuticals acquisition.
Healthcare PharmaceuticalsOwned by AbbVie Inc.
AbbVie's levothyroxine brand for hypothyroidism, first marketed in 1955 and long among the most prescribed medications in the United States.
Healthcare PharmaceuticalsOwned by AbbVie Inc.
AbbVie's natural desiccated thyroid brand derived from porcine thyroid glands, used for hypothyroidism for more than a century and acquired through Forest, Actavis, and Allergan.
Healthcare PharmaceuticalsOwned by IBSA Institut Biochimique S.A.
IBSA Institut Biochimique SA's branded levothyroxine softgel capsule (Tirosint) and liquid solution (Tirosint-SOL), FDA approved for hypothyroidism, formulated without dyes, gluten, lactose, alcohol, or sugar, providing an excipient-free alternative to conventional levothyroxine tablets for patients with sensitivities or absorption issues.
Healthcare PharmaceuticalsOwned by IBSA Institut Biochimique S.A.
IBSA Pharma's liquid levothyroxine oral solution, the first and only FDA-approved liquid levothyroxine, marketed in monodose ampules for hypothyroidism since 2019 in the US.
Market Positioning: Unithroid competes with 5 brands in the same categories, ranging from mass market to luxury positioning.
Geographic Distribution: Competitors are headquartered across multiple regions, indicating global competition in this market segment.
Brand Heritage: Competitor brands range from established heritage brands to newer market entrants, with founding years spanning several decades.
Looking for brands with different ownership structures? These similar brands are not owned by Amneal Pharmaceuticals, Inc., giving you alternative choices that support different corporate structures.
Healthcare PharmaceuticalsOwned by IBSA Institut Biochimique S.A.
IBSA Institut Biochimique SA's branded levothyroxine softgel capsule (Tirosint) and liquid solution (Tirosint-SOL), FDA approved for hypothyroidism, formulated without dyes, gluten, lactose, alcohol, or sugar, providing an excipient-free alternative to conventional levothyroxine tablets for patients with sensitivities or absorption issues.
Tirosint is privately owned, unlike Unithroid which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by IBSA Institut Biochimique S.A.
IBSA Pharma's liquid levothyroxine oral solution, the first and only FDA-approved liquid levothyroxine, marketed in monodose ampules for hypothyroidism since 2019 in the US.
Tirosint-SOL is privately owned, unlike Unithroid which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by TTAM Research Institute
Consumer DNA testing brand now run as a nonprofit under TTAM Research Institute following the 2025 bankruptcy sale of 23andMe Holding Co.
23andMe is privately owned, unlike Unithroid which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by Adcock Ingram Holdings Limited
South African pharmaceutical brand behind Panado and Myprodol, now privately held by Bidvest and NATCO Pharma.
Adcock Ingram is privately owned, unlike Unithroid which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by Global Medical Response
America's largest air ambulance membership network, covering more than 3 million members across 38 states, operated by Global Medical Response.
AirMedCare Network is privately owned, unlike Unithroid which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by Alfa-Pharm CJSC
Armenia's largest pharmaceutical distributor and pharmacy chain, importing medicines from more than 70 global manufacturers since 1996.
Alfa-Pharm is privately owned, unlike Unithroid which is under a publicly traded parent company.
Discover popular brands and companies in the Healthcare & Pharmaceuticals category and related searches from other users.

Consumer DNA testing brand now run as a nonprofit under TTAM Research Institute following the 2025 bankruptcy sale of 23andMe Holding Co.

Abbokinase (urokinase) is a thrombolytic medication historically used for pulmonary embolism and catheter clearance. Originally marketed by Abbott Laboratories, now owned by Microbix Biosystems as Kinlytic. FDA-approved since 1978.

Abbott Laboratories' medical device business spanning cardiovascular, diabetes care (FreeStyle Libre), neuromodulation, and structural heart, generating roughly $20 billion annually.